First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors.

Invest New Drugs · 2017 · PMC5418314 · PMID 28150073

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a slight trendno p-value reported

There was a slight trend towards reduced blood pressure during and immediately post-infusion that normalized by the end of the post-infusion follow-up.

also in 4,078 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.